Quantitative analysis for Kiniksa Pharmaceuticals, Ltd. (KNSA) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (66.0) (grade B). 29 signals analyzed (23 differentiated alt-data).
KNSA stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $54.23 | $45.01 | $53.85 |
| 2026-05-08 | $58.85 | $56.83 | $58.60 |
| 2026-05-20 | $54.51 | $52.31 | $54.28 |
| 2026-06-02 | $47.89 | $46.10 | $46.92 |
| 2026-06-12 | $52.45 | $51.37 | $51.89 |
| 2026-06-25 | $59.73 | $56.86 | $56.89 |
| 2026-07-08 | $67.50 | $63.26 | $64.76 |
| 2026-07-20 | $65.00 | $62.23 | $62.58 |
| 2026-07-30 | $80.51 | $77.74 | $78.20 |
| 2026-08-12 | $79.77 | $76.92 | $78.15 |
| 2026-08-24 | $79.98 | $77.71 | $79.38 |
| 2026-09-03 | $81.41 | $78.84 | $80.47 |
How Kiniksa Pharmaceuticals, Ltd. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company N.V. | $4.2B | — |
| HNGE | Hinge Health, Inc. | $4.2B | — |
| BLLN | BillionToOne, Inc. | $3.8B | — |
| MANE | Veradermics, Incorporated | $4.4B | — |
View all Health Care stocks by valuation and signals →
Kiniksa Pharmaceuticals, Ltd. (KNSA) scores Buy (66.0), and the composite conceals a 56-point disagreement between its dimensions. It is strongest on competitive moat at 85 and technicals at 64, and weakest on analyst consensus at 29. A stock can carry competitive moat that high while analyst consensus sits at 29; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 85 |
| technicals | 64 |
| analyst consensus | 29 |
StoQuant analyzes 29 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Kiniksa Pharmaceuticals, Ltd. (KNSA): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/KNSA"><img src="https://stoquant.com/badge/KNSA.svg" alt="Kiniksa Pharmaceuticals, Ltd. (KNSA) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.